Skip to main content

Table 3 Clinical features and procedural characteristics by antithrombotic treatment group

From: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

  Nothing
n = 93
UFH
n = 153
UFH + Abcx
n = 44
Abcx
n = 65
Bivalirudin
n = 24
Enoxaparin
n = 18
p
Age (years) 61 ± 13 60.3 ± 14 61.3 ± 11 55.4 ± 4 61 ± 11 63.9 ± 9 <0.001
Females 15 (16) 21 (13.7) 6 (13.6) 7 (10.7) 1 (4.2) 4 (22) 0.2
Weight (kg) 77.5 ± 10 81 ± 13 81 ± 12 80 ± 13 81 ± 12 81 ± 17 0.01
Hypertension 51 (54.8) 74 (48.3) 18 (40.9) 30 (46) 14 (58.3) 9 (50) 0.2
Smoking 50 (53.7) 81 (53) 24 (54.5) 43 (66) 17 (70.8) 9 (50) 0.1
Diabetes 23 (24.7) 34 (22.2) 3 (6.8) 13 (20) 4 (16.6) 5 (27.7) 0.04
Dyslipidemia 47 (50.5) 69 (45) 15 (34) 31 (47.6) 15 (62.5) 8 (44) 0.03
Previous stroke 3 (3.2) 8 (5.2) 1 (2.2) 2 (3) 0 1 (5.5) 0.5
Previous infarction 7 (7.5) 14 (9.1) 1 (2.2) 11 (16.9) 4 (16.6) 3 (16.6) 0.03
Peripheral vascular disease 5 (5.4) 6 (3.9) 2 (4.5) 1 (1.5) 1 (4.2) 1 (5.5) 0.05
Coronary surgery 1 (1) 2 (1.3) 0 1 (1.5) 0 0 0.4
SBP at admission (mmHg) 135 ± 28 123 ± 27 117 ± 22 127 ± 24 113 ± 30 120 ± 24 <0.001
HR at admission (bpm) 78 ± 19 77.5 ± 19 75.7 ± 19 79 ± 20 74 ± 19 67 ± 15 0.02
Creatinine (mg/dL) 1.1 ± 0.6 0.9 ± 0.3 1 ± 1 1 ± 0.3 0.9 ± 0.2 1 ± 0.2 <0.001
Baseline hematocrit (%) 40 ± 10 41.5 ± 5 41 ± 6 37 ± 12 40.8 ± 7 38.3 ± 11 <0.001
Anterior infarction 50 (53.7) 62 (40.5) 22 (50) 31 (47.6) 11 (45.8) 9 (50) 0.05
Ejection fraction (%) 46.6 ± 11 50.8 ± 12 51 ± 14 47 ± 13 50 ± 13 50.7 ± 11 0.02
Pain onset to thrombolysis 120 121 105 105 120 88 0.09
Thrombolysis to rescue 167 164 205 168 182 175 0.003
TNK-tPA + enoxaparin 89 (95.6) 144 (94) 39 (88.6) 60 (92.3) 21 (87.5) 17 (94.4) 0.2
Killip class III-IV 12 (13) 12 (7.8) 5 (11.4) 11 (17) 5 (20.8) 0 0.08
Radial access 19 (20.4) 100 (65.3) 31 (70.4) 11 (17) 11 (45.8) 17 (94.4) <0.001
Baseline TIMI 1.7 ± 1.3 1.4 ± 1.3 0.57 ± 1 0.78 ± 1 0.75 ± 1.2 16 ± 1.3 <0.001
Final TIMI 2.8 ± 0.7 2.9 ± 0.5 2.75 ± 0.7 2.7 ± 0.6 2.8 ± 0.6 3 ± 0 0.01
Baseline TIMI 0–1 38 (40.8) 77 (50.3) 36 (81.8) 45 (69.2) 18 (75) 6 (33.3) <0.001
Final TIMI 3 86 (92.5) 143 (93.4) 35 (79.5) 51 (78.4) 22 (91.6) 18 (100) 0.003
Thrombus aspiration 23 (24.7) 56 (36.6) 28 (63.6) 38 (58.4) 13 (54.2) 6 (33.3) 0.001
Number of stents 1.2 ± 0.6 1.3 ± 0.7 1.37 ± 0.9 1.27 ± 0.8 1.08 ± 0.6 1.1 ± 0.5 0.1
Multivessel disease 41 (44) 48 (31.4) 18 (40.9) 27 (41.5) 13 (54.2) 8 (44) 0.04
2nd PCI 7 (7.5) 18 (11.7) 7 (16) 6 (9.2) 5 (20.8) 0 0.1
Clopidogrel load 300 mg 85 (91.4) 126 (82.3) 37 (84) 55 (84.6) 19 (79.2) 11 (61) 0.002
  1. Qualitative variables are shown as n (%) and quantitative variables as mean ± standard deviation, except times, which are shown as medians
  2. Abcx abciximab, HR heart rate, PCI percutaneous coronary intervention, SBP systolic blood pressure, TNK-tPA tenecteplase, UFH unfractionated heparin